A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis

PLoS ONE

Volumn 4, Issue 9, 2009, Pages

  Patwardhan, Gauri A ^a   Zhang, Qian Jin ^b   Yin, Dongmei ^a,g   Gupta, Vineet ^a   Bao, Jianxiong ^c   Senkal, Can E ^d   Ogretmen, Besim ^d   Cabot, Myles C ^e   Shah, Girish V ^a   Sylvester, Paul W ^a   Jazwinski, S Michal ^f   Liu, Yong Yu ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c Louisiana State University Health Sciences Center   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e JOHN WAYNE CANCER INSTITUTE   (United States)

^f TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NANTONG MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; CERAMIDE; CERAMIDE GLUCOSYLTRANSFERASE; DOXORUBICIN; MESSENGER RNA; GLUCOSYLTRANSFERASE; OLIGONUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; TUMOR RESISTANCE; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CELL SURVIVAL; DRUG ANTAGONISM; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; KIDNEY; LIVER; METABOLISM; NUDE MOUSE; TUMOR CELL LINE;

MURINAE; MUS;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSYLTRANSFERASES; HUMANS; KIDNEY; LIVER; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDES;

EID: 70349129967     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006938     Document Type: Article

References (55)

1. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608: 1-22.
2. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58.
3. Liu YY, Han TY, Giuliano AE, Cabot MC (2001) Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J 15: 719-730.
4. Senchenkov A, Litvak DA, Cabot MC (2001) Targeting ceramide metabolism - a strategy for overcoming drug resistance. J Natl Cancer Inst 93: 347-357.
5. Reynolds CP, Maurer BJ, Kolesnick RN (2004) Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett 206: 169-180.
6. Ogretmen B, Hannun YA (2004) Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4: 604-616.
7. Hannun YA (1994) The sphingomyelin cycle and the second messenger function of ceramide. J Biol Chem 269: 3125-3128.
8. Kolesnick R, Hannun YA (1999) Ceramide and apoptosis. Trends Biochem Sci 24: 224-225.
9. Kolesnick R, Fuks Z (2003) Radiation and ceramide-induced apoptosis. Oncogene 22: 5897-5906.
10. Kolesnick R, Altieri D, Fuks Z (2007) A CERTain role for ceramide in taxane-induced cell death. Cancer Cell 11: 473-475.
11. Liu YY, Han TY, Giuliano AE, Cabot MC (1999) Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J Biol Chem 274: 1140-1146.
12. Ogretmen B, Schady D, Usta J, Wood R, Kraveka JM, et al. (2001) Role of ceramide in mediating the inhibition of telomerase activity in A549 human lung adenocarcinoma cells. J Biol Chem 276: 24901-24910.
13. Liu YY, Han TY, Giuliano AE, Ichikawa S, Hirabayashi Y, et al. (1999) Glycosylation of ceramide potentiates cellular resistance to tumor necrosis factor-alpha-induced apoptosis. Exp Cell Res 252: 464-470.
14. Gouaze V, Yu JY, Bleicher RJ, Han TY, Liu YY, et al. (2004) Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol Cancer Ther 3: 633-639.
15. Liu YY, Yu JY, Yin D, Patwardhan GA, Gupta V, et al. (2008) A role for ceramide in driving cancer cell resistance to doxorubicin. FASEB J 22: 2541-2551.
16. Itoh M, Kitano T, Watanabe M, Kondo T, Yabu T, et al. (2003) Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia. Clin Cancer Res 9: 415-423.
17. Xie P, Shen YF, Shi YP, Ge SM, Gu ZH, et al. (2008) Overexpression of glucosylceramide synthase in associated with multidrug resistance of leukemia cells. Leuk Res 32: 475-480.
18. Ruckhaberle E, Karn T, Hanker L, Gatje R, Metzler D, et al. (2009) Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer. J Cancer Res Clin Oncol 135: 81-90.
19. Lavie Y, Cao H, Volner A, Lucci A, Han TY, et al. (1997) Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem 272: 1682-1687.
20. Liu YY, Han TY, Giuliano AE, Hansen N, Cabot MC (2000) Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance. J Biol Chem 275: 7138-7143.
21. Olshefski RS, Ladisch S (2001) Glucosylceramide synthase inhibition enhances vincristine-induced cytotoxicity. Int J Cancer 93: 131-138.
22. Morjani H, Aouali N, Belhoussine R, Veldman RJ, Levade T, et al. (2001) Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets. Int J Cancer 94: 157-165.
23. Liu YY, Han TY, Yu JY, Bitterman A, Le A, et al. (2004) Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells. J Lipid Res 45: 933-940.
24. Gouaze V, Liu YY, Prickett CS, Yu JY, Giuliano AE, et al. (2005) Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res 65: 3861-3867.
25. Dijkhuis AJ, Klappe K, Jacobs S, Kroesen BJ, Kamps W, et al. (2006) PDMP sensitizes neuroblastoma to paclitaxel by inducing aberrant cell cycle progression leading to hyperploidy. Mol Cancer Ther 5: 593-601.
26. Sun YL, Zhou GY, Li KN, Gao P, Zhang QH, et al. (2006) Suppression of glucosylceramide synthase by RNA interference reverses multidrug resistance in human breast cancer cells. Neoplasma 53: 1-8.
27. Agrawal S, Jiang Z, Zhao Q, Shaw D, Cai Q, et al. (1997) Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc Natl Acad Sci U S A 94: 2620-2625.
28. Wang H, Cai Q, Zeng X, Yu D, Agrawal S, et al. (1999) Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration. Proc Natl Acad Sci U S A 96: 13989-13994.
29. Ichikawa S, Sakiyama H, Suzuki G, Hidari KI, Hirabayashi Y (1996) Expression cloning of a cDNA for human ceramide glucosyltransferase that catalyzes the first glycosylation step of glycosphingolipid synthesis. Proc Natl Acad Sci U S A 93: 4638-4643.
30. Watanabe R, Wu K, Paul P, Marks DL, Kobayashi T, et al. (1998) Up-regulation of glucosylceramide synthase expression and activity during human keratinocyte differentiation. J Biol Chem 273: 9651-9655.
31. Fairchild CR, Ivy SP, Kao-Shan CS, Whang-Peng J, Rosen N, et al. (1987) Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells. Cancer Res 47: 5141-5148.
32. Mehta K, Devarajan E, Chen J, Multani A, Pathak S (2002) Multidrug-resistant MCF-7 cells: an identity crisis? J Natl Cancer Inst 94: 1652-1654.
33. Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF (2005) The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 11: 8782-8788.
34. Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, et al. (2001) In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 61: 749-758.
35. Tepel J, Kruse ML, March C, Fiedler A, Kapischke M, et al. (2004) Terminally modified oligodeoxynucleotides directed against p53 in an orthotopic xenograft model: a novel adjuvant treatment strategy for pancreatic ductal carcinoma. Pancreas 28: 1-12.
36. Bogin L, Degani H (2002) Hormonal regulation of VEGF in orthotopic MCF7 human breast cancer. Cancer Res 62: 1948-1951.
37. De Larco JE, Wuertz BR, Manivel JC, Furcht LT (2001) Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents. Cancer Res 61: 2857-2861.
38. Kraveka JM, Li L, Bielawski J, Obeid LM, Ogretmen B (2003) Involvement of endogenous ceramide in the inhibition of telomerase activity and induction of morphologic differentiation in response to all-trans-retinoic acid in human neuroblastoma cells. Arch Biochem Biophys 419: 110-119.
39. Koybasi S, Senkal CE, Sundararaj K, Spassieva S, Bielawski J, et al. (2004) Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. J Biol Chem 279: 44311-44319.
40. Diaz-Montero CM, McIntyre BW (2005) Acquisition of anoikis resistance in human osteosarcoma cells does not alter sensitivity to chemotherapeutic agents. BMC Cancer 5: 39.
41. Rath G, Schneider C, Langlois B, Sartelet H, Morjani H, et al. (2009) De novo ceramide synthesis is responsible for the anti-tumor properties of camptothecin and doxorubicin in follicular thyroid carcinoma. Int J Biochem Cell Biol 41: 1165-1172.
42. Delpy E, Hatem SN, Andrieu N, de Vaumas C, Henaff M, et al. (1999) Doxorubicin induces slow ceramide accumulation and late apoptosis in cultured adult rat ventricular myocytes. Cardiovasc Res 43: 398-407.
43. Ogretmen B, Hannun YA (2001) Updates on functions of ceramide in chemotherapy-induced cell death and in multidrug resistance. Drug Resist Updat 4: 368-377.
44. Senkal CE, Ponnusamy S, Rossi MJ, Bialewski J, Sinha D, et al. (2007) Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas. Mol Cancer Ther 6: 712-722.
45. Swanton C, Marani M, Pardo O, Warne PH, Kelly G, et al. (2007) Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 11: 498-512.
46. Lucci A, Cho WI, Han TY, Giuliano AE, Morton DL, et al. (1998) Glucosylceramide: a marker for multiple-drug resistant cancers. Anticancer Res 18: 475-480.
47. Lavie Y, Cao H, Bursten SL, Giuliano AE, Cabot MC (1996) Accumulation of glucosylceramides in multidrug-resistant cancer cells. J Biol Chem 271: 19530-19536.
48. Liu YY, Cabot MC (2004) Development of a mammalian Tet-on expression cell line: glucosylceramide synthase regulates TNF-alpha-induced apoptosis. Methods Mol Biol 249: 177-192.
49. Zhang Z, Li M, Wang H, Agrawal S, Zhang R (2003) Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci U S A 100: 11636-11641.
50. Marks DL, Dominguez M, Wu K, Pagano RE (2001) Identification of active site residues in glucosylceramide synthase. A nucleotide-binding catalytic motif conserved with processive beta-glycosyltransferases. J Biol Chem 276: 26492-26498.
51. Wu K, Marks DL, Watanabe R, Paul P, Rajan N, et al. (1999) Histidine-193 of rat glucosylceramide synthase resides in a UDP-glucose- and inhibitor (D-threo-1-phenyl-2-decanoylamino-3-morpholinopropan-1-ol)-binding region: a biochemical and mutational study. Biochem J 341 (Pt 2): 395-400.
52. McEachern KA, Fung J, Komarnitsky S, Siegel CS, Chuang WL, et al. (2007) A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab 91: 259-267.
53. Weiss M, Hettmer S, Smith P, Ladisch S (2003) Inhibition of melanoma tumor growth by a novel inhibitor of glucosylceramide synthase. Cancer Res 63: 3654-3658.
54. Tortora G, Bianco R, Damiano V, Fontanini G, De Placido S, et al. (2000) Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production. Clin Cancer Res 6: 2506-2512.
55. Goel S, Desai K, Bulgaru A, Fields A, Goldberg G, et al. (2003) A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumors. Clin Cancer Res 9: 4069-4076.